Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more
Medy-Tox Inc (086900) - Total Liabilities
Latest total liabilities as of September 2025: ₩119.26 Billion KRW
Based on the latest financial reports, Medy-Tox Inc (086900) has total liabilities worth ₩119.26 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medy-Tox Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Medy-Tox Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medy-Tox Inc Competitors by Total Liabilities
The table below lists competitors of Medy-Tox Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qualipoly Chemical Corp
TW:4722
|
Taiwan | NT$3.18 Billion |
|
Scales Corporation Limited
F:S05
|
Germany | €227.41 Million |
|
iHeartMedia Inc Class A
NASDAQ:IHRT
|
USA | $6.88 Billion |
|
Jiangxi Naipu Mining Machinery
SHE:300818
|
China | CN¥1.27 Billion |
|
Mangalore Refinery and Petrochemicals Limited
NSE:MRPL
|
India | ₹222.43 Billion |
|
Vinati Organics Limited
NSE:VINATIORGA
|
India | ₹3.70 Billion |
|
Dynamatic Technologies Limited
NSE:DYNAMATECH
|
India | ₹9.94 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Medy-Tox Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medy-Tox Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medy-Tox Inc (2013–2024)
The table below shows the annual total liabilities of Medy-Tox Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩144.38 Billion | +5.28% |
| 2023-12-31 | ₩137.14 Billion | -18.49% |
| 2022-12-31 | ₩168.24 Billion | -5.60% |
| 2021-12-31 | ₩178.22 Billion | -21.27% |
| 2020-12-31 | ₩226.37 Billion | +39.40% |
| 2019-12-31 | ₩162.38 Billion | +14.01% |
| 2018-12-31 | ₩142.43 Billion | -24.76% |
| 2017-12-31 | ₩189.29 Billion | +7.34% |
| 2016-12-31 | ₩176.35 Billion | +95.80% |
| 2015-12-31 | ₩90.07 Billion | +3.62% |
| 2014-12-31 | ₩86.92 Billion | +364.10% |
| 2013-12-31 | ₩18.73 Billion | -- |